{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-041723","form_type":"8-K","ticker":"AVR","cik":"0002011514","company_name":"Anteris Technologies Global Corp.","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.305680+00:00","generated_at":"2026-05-16T20:39:14.238615+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"medium","headline":"Anteris reports Q3 2025 cash burn; FDA OK to start PARADIGM trial in US","bullets":["FDA approved U.S. recruitment for PARADIGM Trial in Nov 2025; first patients treated in Denmark in Oct 2025.","Q3 2025: R&D expenses $16.8M, SG&A $5.8M; net operating cash outflow 9M $59.3M.","Cash and cash equivalents $9.1M as of Sep 30, 2025.","IPO net proceeds $80M used: $52.7M for DurAVR development, $18.3M for debt repayment and working capital.","Related party payments in Q3: $515k (director fees, CEO, CFO remuneration)."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-041723","json":"https://secwatch.observer/filing/0001140361-25-041723.json","markdown":"https://secwatch.observer/filing/0001140361-25-041723.md","text":"https://secwatch.observer/filing/0001140361-25-041723.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2011514/000114036125041723/0001140361-25-041723-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2011514/000114036125041723/ef20058755_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:39:14.238615+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}